Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jul 15, 2026
Molina Healthcare (MOH) Climbs +19.7% on Illinois Medicaid Win and Analyst Upgrades

Molina Healthcare (MOH) Climbs +19.7% on Illinois Medicaid Win and Analyst Upgrades

Key Takeaways

  • Molina Healthcare shares surged approximately 19.7% in the last 30 days, closing at $241.56 on July 14, 2026, up from $201.87 on June 15, 2026.
  • The rally was fueled by a major Illinois Medicaid contract win, multiple analyst price-target increases, and an index reclassification into the Russell 2500 Value Index.
  • Over the last quarter, the stock extended gains as the company beat Q1 2026 adjusted EPS expectations by a wide margin and reaffirmed full-year guidance during its May investor day.
  • Institutional ownership remains exceptionally high at 98.5%, with several large funds materially increasing their positions in recent months.
  • Investors now look ahead to the Q2 2026 earnings release scheduled for July 22, with analysts expecting management to raise full-year guidance above the current floor of $5.00 per share.

Molina Healthcare (MOH): Company Overview and Market Position

Molina Healthcare, Inc. is a Fortune 500 managed care company that specializes in government-sponsored health insurance programs. Headquartered in Long Beach, California, the company provides Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care delivery model, Molina emphasizes preventive and primary care services, care coordination, and disease management. The company serves approximately 5 million members across the United States and competes with other managed care organizations such as Centene, Elevance Health, and UnitedHealth Group. Investors closely monitor Molina for its exposure to Medicaid policy trends, medical cost ratios, and state-level contract procurement cycles. I also ran a quick comparison using Tickeron’s AI Screener to see how it stacks up against peers in the space.

Recent Stock Performance: +19.7% Gain Over the Last 30 Days

Over the last 30 days, MOH shares climbed from a closing price of $201.87 on June 15, 2026, to $241.56 on July 14, 2026, representing a gain of approximately 19.7%. The upward trajectory accelerated sharply during the final week of June, when the stock jumped from roughly $201 to over $229 in just two trading sessions. The stock also hit a new 52-week high of $243.77 on July 13, 2026. Over the broader quarter, the rally has been even more pronounced. From mid-April levels around $170–$180, Molina shares have advanced more than 35%, pushing the 50-day simple moving average to approximately $200 and the 200-day moving average to roughly $174. The stock's year-to-date gain has approached 40%, reflecting a sustained rebound from the $121.06 low reached during the trailing twelve-month period.

Key Catalysts Behind the Last 30 Days Rally

Several catalysts converged to power Molina's approximately 19.7% advance. The most impactful event was the June 10 announcement that the Illinois Department of Healthcare and Family Services intends to award a Medicaid Managed Care contract to Molina's Illinois subsidiary. The HealthChoice Illinois contract, covering approximately 3.1 million Medicaid beneficiaries, carries an initial four-and-a-half-year term with an option for an additional five-and-a-half years and is set to begin January 1, 2027. Shortly afterward, RBC Capital initiated coverage on Molina with a Sector Perform rating and a $216 price target, highlighting a path to $25 in adjusted EPS by 2029. In late June, Weiss Ratings upgraded Molina from a "sell" to a "hold" rating. The stock also benefited from an index reclassification: Molina was removed from several Russell growth and defensive indices and added to the Russell 2500 Index and Russell 2500 Value Benchmark, which drove incremental passive and value-oriented fund flows. Further supporting sentiment, TD Cowen raised its price target to $230 from $163, Truist Financial lifted its target to $250 from $205, and Sanford C. Bernstein maintained an Outperform rating with a $286 price target. Wells Fargo also raised its target to $235 from $159.

Drivers of the Broader Quarterly Advance

The broader quarterly rally was anchored by Molina's Q1 2026 earnings report on April 22, where adjusted EPS of $2.35 handily beat the consensus estimate of $1.57. Although premium revenue of $10.2 billion came in slightly below expectations and reflected a 3.1% year-over-year decline, the earnings beat and management's reaffirmation of full-year guidance at approximately $42 billion in premium revenue and at least $5.00 in adjusted EPS provided a stabilizing catalyst. The company's May 8 investor day reinforced confidence with a multi-year roadmap targeting $25 in adjusted EPS by 2029, driven by organic growth, new contract wins, and margin restoration. Institutional accumulation was another powerful tailwind: Madison Avenue Partners LP disclosed a new $110 million position, the State of Michigan Retirement System increased its stake by 1,568%, and AQR Capital Management boosted its holdings by 217%. The planned exit from the Medicare Advantage-Part D product and a strategic shift toward dual-eligible integrated care products further reshaped the investment narrative toward long-term margin recovery.

Exploring Data-Driven Strategies with Tickeron

For traders seeking data-driven approaches to stocks like MOH, Tickeron’s Trending AI Robots page offers a curated selection of top-performing AI trading bots. While Tickeron hosts hundreds of AI-driven trading bots that collectively trade thousands of tickers across global markets, only the most relevant and consistently high-performing strategies appear in the Trending section. These bots span a variety of methodologies, including trend-following, mean-reversion, breakout, and pattern-recognition strategies, operating across different timeframes and performance benchmarks. Each bot's track record, win rate, and risk profile are transparently displayed, allowing traders to evaluate strategies before committing capital. Exploring the Trending AI Robots page can help investors identify automated strategies aligned with their trading objectives. One thing that stands out to me is how these tools can surface ideas that complement traditional fundamental analysis.

What Investors Should Watch Next for MOH

The most immediate catalyst is Molina's Q2 2026 earnings report, due after market close on July 22, 2026. Analysts project EPS of approximately $1.37 on revenue of $10.82 billion. More importantly, management has signaled it will update full-year 2026 guidance based on first-half operating results, and several analysts including TD Cowen expect the company to raise its EPS outlook above the current floor of $5.00. Key metrics to monitor include the consolidated medical care ratio, which analysts expect at 92.4% for Q2, and Medicaid membership trends following the expected 6% membership decline for 2026. Longer term, the Illinois Medicaid contract implementation, the transition toward dual-eligible integrated care products, and the trajectory of Medicaid rate adequacy as states face budget pressures tied to OBBBA provisions in 2028 remain critical variables. With the stock trading near consensus analyst price targets, the upcoming earnings call will likely set the tone for the next leg of MOH's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MOH

MOH in downward trend: price may drop because broke its higher Bollinger Band on August 14, 2026

MOH broke above its upper Bollinger Band on August 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In of the 39 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where MOH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

MOH moved below its 50-day moving average on August 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MOH crossed bearishly below the 50-day moving average on August 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MOH's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on MOH as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MOH just turned positive on August 13, 2026. Looking at past instances where MOH's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 225 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.507) is normal, around the industry mean (3.666). MOH's P/E Ratio (1251.812) is considerably higher than the industry average of (149.731). Projected Growth (PEG Ratio) (1.781) is also within normal values, averaging (1.216). MOH's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (0.231) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 66.74B. The market cap for tickers in the group ranges from 1.01M to 350.16B. UNH holds the highest valuation in this group at 350.16B. The lowest valued company is IHGP at 1.01M.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -4%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was 45%. ELV experienced the highest price growth at 0%, while CLOV experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 48
Price Growth Rating: 48
SMR Rating: 79
Profit Risk Rating: 89
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
MOH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of health care services to persons eligible for Medicaid

Industry ManagedHealthCare

Profile
Details
Industry
Managed Health Care
Address
200 Oceangate
Phone
+1 562 435-3666
Employees
18000
Web
https://www.molinahealthcare.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.